There is also evidence to support that CDKN3 in cervical cancer (CC) can not only be used as a useful marker that survives and selects additional chemotherapy or specific targeted cancer treatment but also as a specific small drug for developing anti-CC potential target. This evidence concerns the gene CDKN3 and cancer.